Despite a large body of evidence supporting the idea of neuroprotection by TTR [29,30,31,32], substantially related to decreased levels of TTR in both CSF and plasma of AD patients, the cause of TTR reduction in AD is not known yet. The gene discussed is TTR; the disease is Alzheimer disease.